

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.:

13/082

Application of: Thibeault, D. et al

) Art Unit:

1648

Serial No. Filed

: 10/017,736 : December 14, 2001) Examiner: Mosher, Mary

) Confirmation No.: 8889

For

: Purified Active HCV NS2/3 Protease

USPTO

Box Sequence

Room 1B03 Mail Room

Crystal Plaza 2

2011 South Clark Place

Arlington, VA 22202

STATEMENT BY ATTORNEY UNDER 37 C.F.R. § 1.821(f) REGARDING SUBSTITUTE SEQUENCE LISTING

Sir:

Pursuant to a telephone message from Examiner Mosher, submitted herewith is a Substitute Sequence Listing in computer readable format.

Attorney for Applicants affirms that the information recorded in computer readable form is identical to the written Substitute Sequence Listing which was originally submitted on August 22, 2003.

Respectfully submitted,

Susan K. Pocchiari

Attorney for Applicant(s)

Reg. No. 45,016

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877

Tel.: (203) 798-5648 Date: February 5, 2004